FDA Approves New Treatment for Alexander Disease
The drug Zanvastro offers a new option for adults and children to help stabilize motor function.
Updated on Oct. 29, 2026 in Alzheimer’s
Live Poll
Should regulators expedite approvals for drugs treating rare, fatal diseases despite limited clinical trial populations?
The FDA has approved Zanvastro (zilganersen) to treat Alexander disease, a rare genetic disorder. The medication is now available for patients in the United States as a new treatment option for this condition.
Why it matters
Alexander disease previously lacked direct treatment options, leaving families with few medical interventions. This approval provides a first-of-its-kind therapy designed to address the underlying cause of the condition.
Clinical trial results from 54 pediatric and adult participants showed that Zanvastro can stabilize or improve motor skills and maintain walking speeds. The effectiveness of the drug, which was tested across 13 sites in eight countries, is currently under observation for long-term impacts.
The players
FDA
The federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
Zanvastro
A brand name for zilganersen, an antisense oligonucleotide therapy used to treat Alexander disease.
The details
Zanvastro is an antisense oligonucleotide designed to reduce the production of the GFAP protein, which accumulates in excess in those with Alexander disease. The medication is administered via an injection into the spinal canal once every three months. Common side effects include back pain, headache, cough, vomiting, and injection site pain, with a specific FDA warning regarding the potential for aseptic meningitis.
Timeline
Clinical trials in humans began in 2021.
The FDA approved Zanvastro on October 29, 2026.
Health Landscape
This development follows the established trend in the development of antisense oligonucleotide therapies for rare genetic diseases. It marks a significant shift in the landscape of neurological care by providing a targeted intervention where standard of care was previously limited.
Patients and their families should discuss the potential benefits and risks, including the risk of aseptic meningitis, with their neurologist. Regular monitoring of injection sites and potential side effects is a recommended part of the care routine for those receiving this treatment.
The takeaway
Zanvastro provides a new, spinal-administered treatment option for individuals living with Alexander disease. Patients and caregivers should prioritize consistent monitoring for side effects like headache and back pain while discussing the new therapy with their healthcare provider.
Further reading
For more on managing neurological conditions, visit our Alzheimer’s section.
Source note: This article includes information reported by ScienceAlert.
Live Poll
Should regulators expedite approvals for drugs treating rare, fatal diseases despite limited clinical trial populations?
